Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and…
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a…
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall…
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor…
Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 - 4 ClearPoint Neuro Announces Full…
LUND, SWEDEN / ACCESSWIRE / June 1, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today gave a…
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer…
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to…